Ironwood Pharmaceuticals Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Ironwood Pharmaceuticals Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- IRWD
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001446847
Board of directors
-
Alexander J. Denner · DirectorSince 2023
-
Andrew Dreyfus · DirectorSince 2023
-
Catherine Moukheibir · DirectorSince 2023
-
Jay Shepard · DirectorSince 2023
-
Jon R. Duane · DirectorSince 2023
-
Julie McHugh · DirectorSince 2023
-
Mark G. Currie · DirectorSince 2023
-
Marla L. Kessler · DirectorSince 2023
-
Thomas A. Mccourt · Director · Chief Executive OfficerSince 2023
Chief executives
Thomas A. Mccourt
· Chief Executive Officer
Dates unknown
Board connections
5 of this board's directors also sit on 5 other boards.
- via Andrew Dreyfus
- via Jay Shepard
- via Julie McHugh
- via Catherine Moukheibir
- via Thomas A. Mccourt
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 13, 2025 | Alexander J. Denner Director, 10% owner | Grant or award | +24,193 | — | — |
| Jun 10, 2025 | Marla L. Kessler Director | Grant or award | +45,000 | — | — |
| Jun 10, 2025 | Jay Shepard Director | Grant or award | +45,000 | — | — |
| Jun 10, 2025 | Catherine Moukheibir Director | Grant or award | +45,000 | — | — |
| Jun 10, 2025 | Jon R. Duane Director | Grant or award | +45,000 | — | — |
| Jun 10, 2025 | Mark G. Currie Director | Grant or award | +45,000 | — | — |
| Jun 10, 2025 | Julie McHugh Director | Grant or award | +45,000 | — | — |
| Jun 10, 2025 | Andrew Dreyfus Director | Grant or award | +45,000 | — | — |
| Jun 10, 2025 | Alexander J. Denner Director, 10% owner | Grant or award | +45,000 | — | — |
| May 20, 2025 | Thomas A. Mccourt Director, Officer (Chief Executive Officer) | Grant or award | +540,000 | — | — |
| May 16, 2025 | Thomas A. Mccourt Director, Officer (Chief Executive Officer) | Open-market sale | −13,353 | $0.58 | $7,745 |
| May 16, 2025 | Gaskins Tammi L Officer (Chief Commercial Officer) | Open-market sale | −2,563 | $0.58 | $1,487 |
| Feb 10, 2025 | Silver Ronald Officer (Principal Accounting Officer) | Open-market sale | −12,048 | $1.76 | $21,204 |
| Feb 10, 2025 | Thomas A. Mccourt Director, Officer (Chief Executive Officer) | Open-market sale | −139,064 | $1.76 | $244,753 |
| Feb 10, 2025 | Shetzline Michael Officer (SVP, CMO, Head-Res&Drug) | Grant or award | +133,333 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.